Trials / Terminated
TerminatedNCT00431340
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Valerio Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This open-label study will assess anti-tumor activity and safety of belinostat in combination with bortezomib (Velcade®) in multiple myeloma patients refractory to or relapsed from at least one prior bortezomib-containing regimen. Subjects will be administered both PXD101 and bortezomib on the same days: i.e. days 1, 4, 8, and 11 of a 3-week cycle, for up to 8 cycles.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PXD101 |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2007-06-01
- Completion
- 2007-06-01
- First posted
- 2007-02-05
- Last updated
- 2015-07-08
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00431340. Inclusion in this directory is not an endorsement.